- Published on
KembaraXtra-Medicine – Atrial Fibrillation
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by chaotic atrial electrical activity and ineffective atrial contraction, resulting in an irregularly irregular ventricular rhythm. It develops when structural or electrophysiologic abnormalities of the atria promote abnormal impulse formation or conduction. Ventricular rate depends on atrioventricular (AV) nodal conduction, which is influenced by autonomic tone, medications, and intrinsic AV nodal disease.
AF is classified by the American College of Cardiology (ACC) and American Heart Association (AHA) into paroxysmal AF, which terminates spontaneously or with intervention within seven days; persistent AF, which lasts longer than seven days and includes early persistent AF (7 days to less than 3 months) and long-standing persistent AF (more than 1 year); and permanent AF, in which both patient and clinician decide not to pursue rhythm restoration. Additional clinical categories include lone AF in younger patients without structural heart disease, nonvalvular AF (absence of moderate-to-severe mitral stenosis or mechanical valve), secondary AF due to a reversible precipitating condition, and silent AF detected incidentally on electrocardiography.
The prevalence of AF increases markedly with age and affects more than three million people in the United States. It is more common in men than women and more frequently diagnosed in white populations. Stroke is the most serious complication, with AF conferring a two- to sevenfold increased risk of ischemic stroke. Stroke risk rises substantially with advancing age and comorbidities, independent of whether AF is paroxysmal or persistent.
Clinical presentation varies widely. Patients may experience palpitations, fatigue, dizziness, dyspnea, chest discomfort, or reduced exercise tolerance, while others remain asymptomatic. Physical examination typically reveals an irregularly irregular pulse and heart rhythm. AF may also present with thromboembolic complications such as ischemic stroke or systemic embolism.
The pathophysiology of AF involves atrial fibrosis, loss of atrial muscle mass, and abnormal impulse generation, often originating from the pulmonary veins. Both reentrant and focal mechanisms contribute. Common etiologies include hypertension, valvular heart disease, coronary artery disease, heart failure, cardiomyopathies, pulmonary disorders, hyperthyroidism, obesity, electrolyte disturbances, systemic illness, alcohol use, medications, and postoperative stress.
Diagnosis is confirmed by electrocardiography showing absent P waves, fibrillatory baseline activity, and an irregular ventricular response. Evaluation includes history, physical examination, ECG, transthoracic echocardiography to assess structural heart disease, and laboratory testing to identify secondary causes such as thyroid dysfunction or electrolyte abnormalities. Transesophageal echocardiography is useful to detect left atrial thrombus when cardioversion or ablation is considered.
Management of acute AF depends on hemodynamic stability. Hemodynamically unstable patients require immediate synchronized electrical cardioversion. Stable patients are typically managed initially with rate control using beta-blockers, nondihydropyridine calcium channel blockers, or digoxin in selected cases. Rhythm control with pharmacologic or electrical cardioversion may be considered based on symptoms, duration of AF, and patient preference.
Long-term management involves either rate control or rhythm control strategies, both of which require appropriate anticoagulation to reduce stroke risk. Large trials have shown no significant difference in mortality between rate and rhythm control strategies, although early rhythm control may benefit selected patients. Risk factor modification, including treatment of hypertension, obesity, sleep apnea, and alcohol avoidance, is essential in reducing AF burden.
Stroke prevention is central to AF management. The CHA₂DS₂-VASc score is used to estimate thromboembolic risk and guide anticoagulation decisions. Oral anticoagulation is recommended for patients at moderate to high risk, with direct oral anticoagulants preferred over warfarin in eligible patients. Anticoagulation decisions are independent of AF type and must balance bleeding risk, commonly assessed using the HAS-BLED score.
Nonpharmacologic therapies include catheter ablation, which is effective for symptomatic, drug-refractory AF, particularly paroxysmal AF. Pulmonary vein isolation is the cornerstone of ablation therapy, with high success rates in experienced centers. Surgical approaches such as the Cox-Maze procedure may be used in selected patients, often during concomitant cardiac surgery.
AF is associated with increased mortality, heart failure progression, myocardial infarction, and reduced quality of life. Prognosis depends on underlying heart disease, comorbidities, atrial size, and duration of AF. Referral to a cardiologist or electrophysiologist is recommended when considering antiarrhythmic therapy, catheter ablation, or complex anticoagulation decisions.
Early recognition, appropriate anticoagulation, individualized rate or rhythm control, and aggressive management of risk factors are essential to reducing morbidity and mortality associated with atrial fibrillation.
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by chaotic atrial electrical activity and ineffective atrial contraction, resulting in an irregularly irregular ventricular rhythm. It develops when structural or electrophysiologic abnormalities of the atria promote abnormal impulse formation or conduction. Ventricular rate depends on atrioventricular (AV) nodal conduction, which is influenced by autonomic tone, medications, and intrinsic AV nodal disease.
AF is classified by the American College of Cardiology (ACC) and American Heart Association (AHA) into paroxysmal AF, which terminates spontaneously or with intervention within seven days; persistent AF, which lasts longer than seven days and includes early persistent AF (7 days to less than 3 months) and long-standing persistent AF (more than 1 year); and permanent AF, in which both patient and clinician decide not to pursue rhythm restoration. Additional clinical categories include lone AF in younger patients without structural heart disease, nonvalvular AF (absence of moderate-to-severe mitral stenosis or mechanical valve), secondary AF due to a reversible precipitating condition, and silent AF detected incidentally on electrocardiography.
The prevalence of AF increases markedly with age and affects more than three million people in the United States. It is more common in men than women and more frequently diagnosed in white populations. Stroke is the most serious complication, with AF conferring a two- to sevenfold increased risk of ischemic stroke. Stroke risk rises substantially with advancing age and comorbidities, independent of whether AF is paroxysmal or persistent.
Clinical presentation varies widely. Patients may experience palpitations, fatigue, dizziness, dyspnea, chest discomfort, or reduced exercise tolerance, while others remain asymptomatic. Physical examination typically reveals an irregularly irregular pulse and heart rhythm. AF may also present with thromboembolic complications such as ischemic stroke or systemic embolism.
The pathophysiology of AF involves atrial fibrosis, loss of atrial muscle mass, and abnormal impulse generation, often originating from the pulmonary veins. Both reentrant and focal mechanisms contribute. Common etiologies include hypertension, valvular heart disease, coronary artery disease, heart failure, cardiomyopathies, pulmonary disorders, hyperthyroidism, obesity, electrolyte disturbances, systemic illness, alcohol use, medications, and postoperative stress.
Diagnosis is confirmed by electrocardiography showing absent P waves, fibrillatory baseline activity, and an irregular ventricular response. Evaluation includes history, physical examination, ECG, transthoracic echocardiography to assess structural heart disease, and laboratory testing to identify secondary causes such as thyroid dysfunction or electrolyte abnormalities. Transesophageal echocardiography is useful to detect left atrial thrombus when cardioversion or ablation is considered.
Management of acute AF depends on hemodynamic stability. Hemodynamically unstable patients require immediate synchronized electrical cardioversion. Stable patients are typically managed initially with rate control using beta-blockers, nondihydropyridine calcium channel blockers, or digoxin in selected cases. Rhythm control with pharmacologic or electrical cardioversion may be considered based on symptoms, duration of AF, and patient preference.
Long-term management involves either rate control or rhythm control strategies, both of which require appropriate anticoagulation to reduce stroke risk. Large trials have shown no significant difference in mortality between rate and rhythm control strategies, although early rhythm control may benefit selected patients. Risk factor modification, including treatment of hypertension, obesity, sleep apnea, and alcohol avoidance, is essential in reducing AF burden.
Stroke prevention is central to AF management. The CHA₂DS₂-VASc score is used to estimate thromboembolic risk and guide anticoagulation decisions. Oral anticoagulation is recommended for patients at moderate to high risk, with direct oral anticoagulants preferred over warfarin in eligible patients. Anticoagulation decisions are independent of AF type and must balance bleeding risk, commonly assessed using the HAS-BLED score.
Nonpharmacologic therapies include catheter ablation, which is effective for symptomatic, drug-refractory AF, particularly paroxysmal AF. Pulmonary vein isolation is the cornerstone of ablation therapy, with high success rates in experienced centers. Surgical approaches such as the Cox-Maze procedure may be used in selected patients, often during concomitant cardiac surgery.
AF is associated with increased mortality, heart failure progression, myocardial infarction, and reduced quality of life. Prognosis depends on underlying heart disease, comorbidities, atrial size, and duration of AF. Referral to a cardiologist or electrophysiologist is recommended when considering antiarrhythmic therapy, catheter ablation, or complex anticoagulation decisions.
Early recognition, appropriate anticoagulation, individualized rate or rhythm control, and aggressive management of risk factors are essential to reducing morbidity and mortality associated with atrial fibrillation.
0 Comments
